ABSTRACT-The effects of peripheral administration of 6-(R)-5,6,7,8-tetrahydro-L erythrobiopterin dihydrochloride (R-THBP), a natural cofactor for tyrosine and try ptophan hydroxylases, were investigated in mice treated with a competitive inhibitor of tyrosine hydroxylase, a-methyltyrosine (a-MT). A subcutaneous dose of 250 mg/kg of a-MT decreased markedly both ambulatory activity and cerebral contents of nor epinephrine, dopamine and their metabolites in mice. An intraperitoneal dose of 100 mg/kg of R-THBP, which did not alter ambulatory activities in normal mice, im proved the hypoactivity in a-MT-treated mice. Moreover, R-THBP at intraperitoneal doses of 60 and 100 mg/kg inhibited the impairment of cerebral catecholamine metabo lism induced by a-MT in mice. We suggest that the reversal of the a-MT effects by R-THBP might be due to reactivation of tyrosine hydroxylase in the central nervous system. 6-(R)-5,6,7,8-Tetrahydro-L-erythrobiopterin dihydrochloride (R-THBP) is a natural cofac tor for tyrosine and tryptophan hydroxylases (1-4), the initial and rate-limiting enzymes in monoamine biosynthesis (5). Intracerebro ventricular injection of R-THBP into rats in creased the accumulation of 3,4-dihydroxy phenylalanine (DOPA) and 5-hydroxytry ptophan (5-HTP) after inhibition of aromatic L-amino acid decarboxylase and caused an in crease in dopamine (DA) and serotonin (5 HT) metabolites in the brain (6). However, it was reported that an intraperitoneal injection of THBP does not change the levels of 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), 3,4 dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in rat brain (7).
ABSTRACT-The effects of peripheral administration of 6-(R)-5,6,7,8-tetrahydro-L erythrobiopterin dihydrochloride (R-THBP), a natural cofactor for tyrosine and try ptophan hydroxylases, were investigated in mice treated with a competitive inhibitor of tyrosine hydroxylase, a-methyltyrosine (a-MT). A subcutaneous dose of 250 mg/kg of a-MT decreased markedly both ambulatory activity and cerebral contents of nor epinephrine, dopamine and their metabolites in mice. An intraperitoneal dose of 100 mg/kg of R-THBP, which did not alter ambulatory activities in normal mice, im proved the hypoactivity in a-MT-treated mice. Moreover, R-THBP at intraperitoneal doses of 60 and 100 mg/kg inhibited the impairment of cerebral catecholamine metabo lism induced by a-MT in mice. We suggest that the reversal of the a-MT effects by R-THBP might be due to reactivation of tyrosine hydroxylase in the central nervous system. 6-(R)-5,6,7,8-Tetrahydro-L-erythrobiopterin dihydrochloride (R-THBP) is a natural cofac tor for tyrosine and tryptophan hydroxylases (1) (2) (3) (4) , the initial and rate-limiting enzymes in monoamine biosynthesis (5) . Intracerebro ventricular injection of R-THBP into rats in creased the accumulation of 3,4-dihydroxy phenylalanine (DOPA) and 5-hydroxytry ptophan (5-HTP) after inhibition of aromatic L-amino acid decarboxylase and caused an in crease in dopamine (DA) and serotonin (5 HT) metabolites in the brain (6) . However, it was reported that an intraperitoneal injection of THBP does not change the levels of 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), 3,4 dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in rat brain (7) .
Similarly, R-THBP peripherally administered had no effect on CSF levels of HVA, 3 methoxy-4-phenylethyleneglycol (MHPG) and 5-HIAA in the rhesus monkey (8) . Thus, the role of this cofactor in biogenic amine synthe sis in vivo under normal conditions remains unclear.
We investigated a possible role of the synthe tic cofactor R-THBP in determining behav ioral activities of animals with normal or abnormal cerebral monoamine synthesizing capacity. Tyrosine hydroxylase activity in the central nervous system was inhibited by a methyltyrosine in vivo. Our data indicate that peripherally-administered R-THBP would im prove centrally mediated behavioral changes in mice.
MATERIALS AND METHODS

Animals
Male ddY mice were purchased at 4 weeks of age from Shizuoka Laboratory Animal Cen ter (Shizuoka, Japan). Five mice per cage (23.5 X 15.5 X 11.0 cm) were housed and maintained under controlled conditions of temperature (23 ± 1"C), humidity (55 ± 5%) and lighting (dark period, 19 : 00-07 : 00 hr) with free access to food and water. The ex periment was conducted when the mice were 5 weeks of age and weighed 25 to 35 g.
Ambulatory activity
The 482 mice were divided into 53 groups, each group consisting of more than 6 mice. The mouse's ambulatory activity was auto matically recorded with a tilting-type ambulo meter (ACTY-303, Bio Medica, Ltd., Osaka, Japan), consisting of a plastic activity cage (20 cm in diameter, 30 cm in height). The ambula tory activities of 10 mice were measured indi vidually at the same time, using 10 ambulo meters.
R-THBP (synthesized at Suntory) was admin istered intraperitoneally immediately after a subcutaneous injection of 250 mg/kg of dl-a methyltyrosine metylester hydrochloride (a MT; Aldrich Chemical, Milwaukee, MO), which is sufficient dose to inhibit tyrosine hy droxylase activity (9) . Ambulatory activity for 1 hr as an index of exploratory activity of different mice was measured at 1, 2, 3, 4, 5, 6, 7 and 8 hr after the drug administration; that is, different groups were used only once for each time point without habituation. Drugs were always administered at 10: 00 hr. R THBP and a-MT were dissolved in 0.1 M phosphate buffer solution containing 6 mM ! ascorbic acid and 3 mM I-cysteine (pH 7.4) and 0.9% physiological saline, respectively.
Biochemical assay
Mice were used in groups of 6-10 animals each. Each animal was decapitated and the head was frozen in liquid nitrogen. The whole brain, except for the cerebellum, was rapidly excised. The tissue samples were weighed and homogenized in 4 ml 0.1 N perchloric acid containing 4,ug/ml dihydrobenzylamine (inter nal standard). The samples were centrifuged at 12000 rpm for 15 min at 4°C. The super natant obtained was used to determine the contents of norepinephrine (NE), DA, DOPAC, HVA, 5-HT and 5-HIAA by high performance liquid chromatography (HPLC) with electrochemical detection (LCEC, Bio analytical Systems, USA). The conditions for LCEC were as follows: mobile phase, 0.1 M citrate buffer (pH 2.72) containing 0.65 mM sodium octyl sulfate, 0.5 mM EDTA 2Na, 0.6 ml/l diethylamine and 4% acetonitrile; applied potential, +750 mV vs. Ag/AgCI; Biophase ODS column (5 ,um in pore size, 250 X 4.6 mm); flow rate and temperature, 1 ml/min and 35°C, respectively. The mobile phase was previously filtered through a 0.45-pm mem brane filter and degassed.
Statistics
The results are presented as the means ± S.E.M. The statistical evaluations of ambula tory activity and cerebral contents of mono amines were carried out by the Mann-Whitney U-test and Student's t-test, respectively. A P value less than 0.05 was considered significant.
RESULTS
Effect on a-MT-induced hypoactivity
An intraperitoneal dose of 100 mg/kg of R THBP itself produced no significant changes as compared with the vehicle-treated group in the ambulatory activity of mice up to 9 hr after the administration (Fig. 1) . A sub cutaneous dose of 250 mg/kg of a-MT began to reduce ambulatory activity from 2 hr after the administration, and the decrease became significant and more remarkable from 4 hr to 9 hr after the administration (Fig. 2) .
R-THBP at the dose of 30 mg/kg had no effect on the a-MT-induced hypoactivity, but at 100 mg/kg, tended to inhibit it from 4 hr to 8 hr after the administration. A significant effect of R-THBP appeared at 8 9 hr after the administration; that is, R-THBP almost completely reversed a-MT-induced hypoactiv ity. Secondly, the dose-related effects of R THBP were studied on a-MT-induced hypoac tivity at the time (8 9 hr after the administra tion) of the significant behavioral effect. As shown in Fig. 3 , R-THBP at an intraperitoneal dose of 60 mg/kg tended to improve a-MT induced hypoactivity. At an inceased dose of 100 mg/kg, the R-THBP effect became more marked and significant. Fig. 3 . Dose-related effects of R-THBP on a-MT-induced hypoactivity in mice. R-THBP or vehicle was administered intraperitoneally immediately after subcutaneous injection of 250 mg/kg of a-MT. Each value expresses the mean ambulatory activity counts for 1 hr from 8 hr to 9 hr after the drug administration (n = 6-28). **: significantly different from the a-MT-treated group at P < 0.01 (Mann-Whitney U-test).
Effect on a-MT-induced decrease in cerebral contents of monoamines A biochemical assay was carried out at the time (8 hr after the administration) of the sig nificant behavioral effect of R-THBP. A sub cutaneous dose of 250 mg/kg of a -MT signifi cantly reduced the cerebral contents of NE, DA, DOPAC and HVA as compared with the vehicle-treated group at 8 hr after the adminis tration (Fig. 4 and Table 1 ). An intraperi toneal dose of 30 mg/kg of R-THBP slightly improved the a-MT-induced decrease in the contents of catecholamines and their metabo lites, but the effect was not significant as com pared with the a-MT-treated group. At a dose of 60 mg/kg, R-THBP significantly improved the impairment of NE and DOPAC levels by a-MT (Fig. 4) ; and when the dose was in creased to 100 mg/kg, there was a significant and more marked improvement in NE, DA, DOPAC and HVA levels ( Table 1) . Neither a-MT alone nor R-THBP combined with a MT had any effects on 5-HT metabolism (data not shown).
DISCUSSION
The present study demonstrated that (i) R THBP, a natural cofactor for tyrosine and tryptophan hydroxylases, improves not only the a -MT-induced hypoactivity of mice but also the decreases in the cerebral contents of Fig. 4 . Effect of R-THBP on the levels of norepinephrine, dopamine and their metabolites in whole brain except the cerebellum of a-MT-treated mice. R-THBP or vehicle was administered intraperitoneally im mediately after subcutaneous injection of 250 mg/kg of a-MT. Cerebral contents of catecholamine and their metabolites were measured 8 hr after the drug administration. Each value represents the mean ± S.E.M. of 6 to 10 mice. *and **: significantly different from the a-MT-treated group at P < 0.05 and P < 0.01, re spectively (Student's t-test). El: saline (s.c.) + vehicle (i.p.), •: a-MT (s.c.) + vehicle (i.p.), ®: a-MT (s.c.) + R-THBP, 30 mg/kg (i.p.), is a-MT (s.c.) + R-THBP, 60 mg/kg (i.p.). catecholamines and their metabolites, and (ii) R-THBP, at the dose at which it inhibits a MT-induced hypoactivity, does not alter the ambulatory activity of normal mice. a-MT is a competitive inhibitor of tyrosine hydroxylase (5, 10) , the enzyme that catalyzes the synthesis of DOPA from tyrosine. Inhibi tion of tyrosine hydroxylase by a-MT is well established to result in a reduction in the rate of norepinephrine and dopamine synthesis in the central nervous system. We also confirmed that catecholamine metabolism is impaired, but indoleamine metabolism is not. The a MT-induced hypoactivity such as sedation or reduction in motor activity results from im paired central catecholaminergic neuron activ ities (11) . In the present study, R-THBP was shown to cause both a significant reversal of a MT-induced hypoactivity and the improving effects on impaired central catecholamine levels. Therefore, the reversal of the a-MT effect by R-THBP may result from reactiva tion of tyrosine hydroxylase through its action as a cofactor for tyrosine hydroxylase. R THBP required much longer latency (at least 4 hr) to reverse the a-MT effect. This finding agrees with observations in mice that an in traperitoneal administration of 300 mg/kg of R-THBP begins to exhibit toxic symptoms such as ptosis, mild tremor or staggering gait from 11 hr after the injection (12) , and that onset of action of peripherally-administered R THBP is much delayed (at least 2-5 hr) in improving the scopolamine-induced memory impairment (12) and enhancing the meth amphetamine-induced hyperactivity without altering the spontaneous locomotor activity of nomal mice (13) . However, R-THBP may re quire much longer latency to restore the a MT effect, since the dose of a-MT used in the present study inhibits markedly tyrosine hy droxylase activity in the rat brain (9) .
The cytosolic levels of R-THBP are general ly considered to be subsaturating for tyrosine hydroxylase and tryptophan hydroxylase in the monoaminergic neurons of normal brain (14, 15) . However, the contents of monoamine neurotransmitters and their metabolites in rat striatum and hippocampus are not increased after systemic administration of THBP (7), and the CSF levels of HVA, MHPG and 5 HIAA in rhesus monkey, are not changed fol lowing an intravenous injection of R-THBP (8) . On the other hand, there are some clini cal lines of evidence that exogenously adminis tered R-THBP enhances monoamine synthesis in abnormal or pathological brains with de creased levels of endogenous R-THBP or in Parkinson's disease (16) and frequently im proves the characteristic symptoms of Parkin son's disease (17, 18) and endogenous depres sion (17, 19) . The present results with R THBP which restored the previously com promised activity of tyrosine hydroxylase in mice are compatible with these clinical find ings. Thus, the reactivation of compromised tyrosine hydroxylase activities by R-THBP may be able to exert beneficial effects on abnormal and pathological brain.
